2. Academic Validation
  3. ErbB2pY -1248 as a predictive biomarker for Parkinson's disease based on research with RPPA technology and in vivo verification

ErbB2pY -1248 as a predictive biomarker for Parkinson's disease based on research with RPPA technology and in vivo verification

  • CNS Neurosci Ther. 2023 Aug 11. doi: 10.1111/cns.14407.
Meng Jin 1 2,  Ruidie Shi 1 2 3,  Daili Gao 1 2,  Baokun Wang 1 2,  Ning Li 1 2,  Xia Li 4,  Attila Sik 5 6 7,  Kechun Liu 1 2,  Xiujun Zhang 3
Affiliations

Affiliations

  • 1 Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Ji'nan, China.
  • 2 Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Ji'nan, China.
  • 3 School of Psychology, North China University of Science and Technology, Tang'shan, China.
  • 4 Mills Institute for Personalized Cancer Care, Fynn Biotechnologies Ltd., Ji'nan, China.
  • 5 Institute of Transdisciplinary Discoveries, Medical School, University of Pecs, Pécs, Hungary.
  • 6 Institute of Clinical Sciences, Medical School, University of Birmingham, Birmingham, UK.
  • 7 Institute of Physiology, Medical School, University of Pecs, Pécs, Hungary.
PMID: 37564024 DOI: 10.1111/cns.14407
Abstract

Aims: This study aims to reveal a promising biomarker for Parkinson's disease (PD) based on research with reverse phase protein array (RPPA) technology for the first time and in vivo verification, which gains time for early intervention in PD, thus increasing the effectiveness of treatment and reducing disease morbidity.

Methods and results: We employed RPPA technology which can assess both total and post-translationally modified proteins to identify biomarker candidates of PD in a cellular PD model. As a result, the phosphorylation (pY-1248) of the epidermal growth factor receptor (EGFR) ErbB2 is a promising biomarker candidate for PD. In addition, lapatinib, an ErbB2 tyrosine kinase inhibitor, was used to verify this PD biomarker candidate in vivo. We found that lapatinib-attenuated dopaminergic neuron loss and PD-like behavior in the zebrafish PD model. Accordingly, the expression of ErbB2pY-1248 significantly increased in the MPTP-induced mouse PD model. Our results suggest that ErbB2pY-1248 is a predictive biomarker for PD.

Conclusions: In this study, we found that ErbB2pY-1248 is a predictive biomarker of PD by using RPPA technology and in vivo verification. It offers a new perspective on PD diagnosing and treatment, which will be essential in identifying individuals at risk of PD. In addition, this study provides new ideas for digging into biomarkers of other neurodegenerative diseases.

Keywords

ErbB2; PD; SH-SY5Y; mouse; reverse phase protein array; zebrafish.

Figures
Products
Inhibitors & Agonists
Other Products